Programme

You may download the final programme below:

FINAL PROGRAMME

 

THURSDAY APRIL 6th 2017

08.30-08.45     ILAE address and opening of the conference
                        E. Perucca (Italy), E. Trinka (Austria), S. Shorvon (UK)

 

08.45-10.45    The nature of status epilepticus: experimental aspects I
                          D. Kullmann (UK), H. Cock (UK)

08.45-09.05       Mitochondrial diseases and status epilepticus
                          S. Rahmen (UK)

09.05-09.25       Discussion

 

09.25-09.45       Circuit mechanisms in status epilepticus
                          J. Kapur (USA)

09.45-10.05       Discussion

 

10.05-10.25       Receptor trafficking
                          J. Kittler (UK)

10.25-10.45       Discussion 

 

10.45-11.15     Break

 

11.15-12.45     The nature of status epilepticus: experimental aspects II
                        M. Rogawski (USA), M. Walker (UK)

11.15-11.35       Epigenetic changes in status epilepticus
                          D. Henshall (Ireland)

11.35-11.55       Discussion

11.55-12.25       Neurotrophic factors and status epilepticus
                          M. Simonato (Italy)

12.25-12.45       Discussion

 

12.45-13.15     Break and posters

13.15-14.15    Satellite symposium 1

 

14.15-16.15     The nature of status epilepticus: clinical aspects I
                         R. Kälviäinen (Finland), G. Bauer (Austria)

14.15-14.35       Next generation sequencing in the diagnosis of encephalitis
                          W.I. Lipkin (USA)

14.35-14.55       Discussion

 

14.55-15.15       Boundary syndromes
                          S. Shorvon (UK)

15.15-15.35       Discussion

 

15.35-15.55       Status epilepticus due to poisons in warfare
                          A. M. Marini (USA)

15.55-16.15       Discussion

 

16.15-16.45     Break

 

16.45-18.05     The nature of status epilepticus: clinical aspects II
                          A. Neligan (UK), I. Unterberger (Austria)
                                   

16.45-17.05      Neuroimaging of status epilepticus
                          S. Meletti (Italy)

17.05-17.25       Discussion

 

17.25-17.45       Treatment gap in developing countries
                          B. Lee (South Korea)

17.45-18.05       Discussion

 

19.30                 Colloquium Dinner

 

FRIDAY APRIL 7th 2017

08.30-10.30     Status epilepticus in the Intensive Care Unit I
                           N. Abend (USA), P. Kaplan (USA)
   

08.30-08.50       NCSE- types and EEG
                          E. Trinka (Austria)

08.50-09.10       Discussion

 

09.10-09.30       Prognostic scales in status epilepticus
                          F. Yuan (China)

09.30-09.50       Discussion

 

09.50-10.10       Anaesthetic treatment of status epilepticus
                          S. Hocker (USA)
                        

10.10-10.30       Discussion

 

10.30-11.00       Break

 

11.00-13.00     Status epilepticus in the Intensive Care Unit and the weaning of anaesthetics
                         T. Bleck (USA), M. Leitinger (Austria)

11.00-11.20       Guidelines for the weaning of anaesthetics
                          H. Colquhoun (USA)

11.20-11.40       Anaesthetic effects on the EEG: Implications for the management of super refractory status epilepticus
                          A. Cole (USA)

11.40-12.00       Discussion on the topic of weaning anaesthetics



12.00-12.20      Long term consequences of intensive care treatments - a critical assessment
                         T. Loddenkemper (USA)

12.20-12.40       Status epilepticus in the elderly
                          I. Leppik (USA)

12.40-13.00       Discussion

 

13.00-14.00     Lunch and posters

 

14.00-15.00     Some regulatory aspects of Status Epilepticus

14.00-14.20       Is Status Epilepticus an entity?
                        S. Shorvon (UK)
                      
14.20-14.40      What evidence do we need to license a drug for status epilepticus?
                         E. Trinka (Austria)

14.40 - 15.00    Discussion

 

15.00-15.30     Break

 

15.30-17.00     Audits and registries
                         S. Basic (Croatia), A. Strzelczyk (Germany)

15.30-15.50       The global audit of refractory status epilepticus
                          S. Hocker (USA) and M. Ferlisi (Italy)

15.50-16.00       Discussion

 

16.00-16.20       SENSE registry for status epilepticus
                          C. Kellinghaus (Germany)

16.20-16.30       Discussion

16.30-17.00      Poster award

17.00-17.30      Group photo

 

SATURDAY APRIL 8th 2017

08.30-10.00     Future perspectives, novel therapy and innovation I
                         S. Hocker (USA), A. Rossetti (Switzerland)

08.30-08.50       Propofol Hemisuccinate
                          M. Rogawski (USA)

08.50-09.00       Discussion

 

09.00-09.20       Valnoctamide and SPD for acute seizures and status epilepticus
                          M. Bialer (Israel)

09.20-09.30       Discussion

 

09.30-09.50       Brivaraceteam
                          E. Trinka (Austria)

09.50-10.00       Discussion

 

10.00-10.30     Break

 

10.30-14.00     Future perspectives, novel therapy and innovation II
                          N. Bharucha (India), S. Ruegg (Switzerland)


10.30-10.50       Perampanel - an oral AMPA antaogonist
                          A. Rohracher (Austria)

10.50-11.00      Discussion

 

11.00-11.20       Place of neurosteroids in the treatment of status epilepticus 
                          A. Rossetti (Switzerland)

11.20-11.30       Discussion

 

11.30-11.50       Ketamine
                          J. Höfler (Austria)

11.50-12.00       Discussion

 

12.00 - 12.30     Break

 

12.30-12.50       New modes of administration
                          J. Cloyd (USA)

12.50-13.00       Discussion

 

13.00 -13.20       Canine status epilepticus - implications for humans
                          W. Löscher (Germany)

13.20 - 13.30      Discussion

 

13.30-13.50      Reactive oxygen species in status epilepticus
                          M. Walker (UK)

13.50-14.00       Discussion

 

14.00-14.20       Update ESET Trial
                          J. Kapur (USA)

14.20-14.30       Discussion

 

14.30-14.15     Concluding remarks
                        S. Shorvon (UK), E. Trinka (Austria)

 

                        Farewell Gulyas